A Pharmacokinetic Study of YN001 in Healthy Participants

StatusSuspended
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment suspended Sponsor's reason: The study was suspended at the request of the Sponsor. Show 5 more changesShow less
    • Primary completion pushed from Feb 4, 2026 to Sep 2026
    • Primary endpoints: details revised at 1 of 8 entries
    • Study completion pushed from Feb 18, 2026 to Sep 2026
    • Eligibility criteria expanded, about 34 words
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Dec 4, 2025 to Feb 4, 2026
    • Study completion date: Dec 18, 2025 to Feb 18, 2026
    • Start date changed from estimate of Oct 27, 2025 to Nov 18, 2025
    • Site details revised
  3. Secondary endpoints: 2 to 6v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 1, single-center, open-label study designed to evaluate the pharmacokinetics (PK), safety, and immunogenicity following a single dose administration in healthy adult volunteers.
Trial Details
NCT Number NCT07190885
Lead Sponsor Beijing Inno Medicine Co., Ltd.
Conditions
(from sponsor)		 Healthy Volunteers
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov